Drug Search Results
More Filters [+]


Alternative Names: acenocoumarol, acenocumarol
Latest Update: 2024-06-04
Latest Update Note: Clinical Trial Update

Product Description

Acenocoumarol is a hydroxycoumarin that is warfarin in which the hydrogen at position 4 of the phenyl substituent is replaced by a nitro group. It has a role as an anticoagulant and an EC [NAD(P)H dehydrogenase (quinone)] inhibitor. It is a C-nitro compound, a hydroxycoumarin and a methyl ketone.

Mechanisms of Action: Vitamin K Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Algeria | Argentina | Austria | Belgium | Bosnia | Bulgaria | Canada | Chile | Egypt | France | Greece | Hungary | India | Ireland | Italy | Lebanon | Lithuania | Luxembourg | Mexico | Morocco | Netherlands | Peru | Poland | Portugal | Romania | Russia | Serbia | Slovenia | Spain | Switzerland | Tunisia | United Kingdom | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Acenocoumarol

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases



Trial Status


Primary Completion Date

Probability of Success

Recent News Events